AxoGen (NASDAQ:AXGN) Downgraded by StockNews.com to “Hold”

AxoGen (NASDAQ:AXGN) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 price objective on shares of AxoGen in a research note on Friday, January 19th.

AxoGen Stock Performance

Shares of NASDAQ:AXGN traded down $0.12 on Monday, hitting $5.67. The company’s stock had a trading volume of 472,285 shares, compared to its average volume of 400,912. The company has a market capitalization of $247.84 million, a price-to-earnings ratio of -11.34 and a beta of 1.07. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.23 and a current ratio of 3.43. AxoGen has a 12 month low of $3.45 and a 12 month high of $10.83. The stock’s 50-day moving average is $7.76 and its two-hundred day moving average is $7.49.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.11. The firm had revenue of $42.92 million during the quarter, compared to analyst estimates of $42.70 million. AxoGen had a negative net margin of 12.99% and a negative return on equity of 22.18%. On average, equities research analysts forecast that AxoGen will post -0.46 EPS for the current year.

Insider Buying and Selling

In related news, Director Gregory Gene Freitag sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $9.00, for a total value of $225,000.00. Following the sale, the director now directly owns 271,594 shares in the company, valued at approximately $2,444,346. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Karen L. Zaderej sold 39,280 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $301,670.40. Following the completion of the sale, the chief executive officer now directly owns 1,124,565 shares of the company’s stock, valued at $8,636,659.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gregory Gene Freitag sold 25,000 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $9.00, for a total value of $225,000.00. Following the completion of the transaction, the director now owns 271,594 shares of the company’s stock, valued at approximately $2,444,346. The disclosure for this sale can be found here. Insiders have sold a total of 111,201 shares of company stock valued at $928,054 over the last three months. Company insiders own 7.00% of the company’s stock.

Institutional Trading of AxoGen

Several institutional investors and hedge funds have recently bought and sold shares of AXGN. Tocqueville Asset Management L.P. increased its position in shares of AxoGen by 98.7% in the third quarter. Tocqueville Asset Management L.P. now owns 934,900 shares of the medical equipment provider’s stock worth $4,674,000 after acquiring an additional 464,500 shares in the last quarter. Rice Hall James & Associates LLC acquired a new position in AxoGen in the 1st quarter worth approximately $1,236,000. Panagora Asset Management Inc. raised its stake in AxoGen by 69.8% during the 4th quarter. Panagora Asset Management Inc. now owns 165,461 shares of the medical equipment provider’s stock valued at $1,130,000 after purchasing an additional 68,001 shares during the period. White Pine Capital LLC lifted its holdings in shares of AxoGen by 127.1% in the fourth quarter. White Pine Capital LLC now owns 107,733 shares of the medical equipment provider’s stock valued at $736,000 after purchasing an additional 60,300 shares in the last quarter. Finally, Keeley Teton Advisors LLC lifted its holdings in shares of AxoGen by 135.3% in the fourth quarter. Keeley Teton Advisors LLC now owns 84,725 shares of the medical equipment provider’s stock valued at $579,000 after purchasing an additional 48,725 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.